Home – Alzheimer’s Gut Microbiome Project
The Alzheimer Gut Microbiome Project (AGMP) is an initiative funded by the National Institute of Aging (NIA) to investigate the role of the gut microbiome and metabolome in Alzheimer's Disease pathogenesis and in the development of neuropsychiatric symptoms. It brings together 40 scientists from 14 academic institutions, to define the role of complex bidirectional interconnections involving the diet, exposome, lifestyle influences, gut microbiome, genome on the metabolome to inform about individuality, vulnerability, and unique trajectories of Alzheimer’s disease (AD). By measuring thousands of chemicals produced by a commensal relationship between the host and the gut microbes, we aim to define how the brain is connected and influenced by peripheral factors that contribute to disease pathogenesis. Big data is generated and used to enable a precision medicine approach for the study of Alzheimer’s Disease.
- Examine the association between the gut microbiome and AD phenotypes.
- Define compositional and functional changes in the gut microbiome and related human metabolome changes across stages of AD, correlated with cognitive phenotypes; and evaluate the effect of diet and lifestyle on these associations.
- Define the biochemical axis of communication between the gut microbiome and the brain and identify metabolites that contribute to AD endophenotypes.
- Examine mechanistic links between the activity of the gut microbiome and AD pathogenesis and identify new approaches for AD prevention that target the gut-brain axis.
The AGMP is funded by NIH grant U19AG063744 awarded under the Accelerating Medicines Partnership - Alzheimer's Disease (AMP-AD) initiative of the National Institute on Aging (NIA).